A nemia is an independent predictor of morbidity and mortality in patients with heart failure (HF) (1) (2) (3) (4) (5) (6) . The estimated prevalence of anemia in HF patients depends on the severity of failure and can range from 20% to 80% in those with New York Heart Association functional class III to IV symptoms (7, 8) . A comparable rate has been reported in HF patients receiving left ventricular assist device (LVAD) support. In 1 retrospective study, anemia was present in almost one-half of 65 patients after implantation of LVAD and was associated with higher rates of all-cause mortality despite improvement in end-organ perfusion (9) . Mechanisms for the development of anemia in patients with LVAD support are multifactorial but often involve a chronic inflammatory state created by the immune system reacting to LVAD biomaterial (10) (11) (12) . The inflammatory milieu that ensues may suppress erythropoiesis (9) by inhibiting production of erythropoietin and diminishing its effectiveness similar to the pathophysiology of anemia of chronic disease (10) . It has been demonstrated that anemic LVAD patients have lower than expected circulating erythropoietin levels (9) . This has led some clinicians to treat LVAD-supported patients with erythropoiesis stimulating agents (ESAs).
ESAs are ideal for patients destined for transplantation, as ESA treatment increases hemoglobin levels, thereby reducing the need for transfusions and subsequent risk of developing anti-HLA antibodies (13) (14) (15) (16) . Allosensitization most commonly results from previous blood transfusions and can complicate procurement of an appropriate donor heart, delaying time until transplantation (17) . Post-transplant, allosensitization may lead to higher rates of organ rejection and allograft vasculopathy (17) . ESAs were converted to darbepoetin equivalents using a fixed conversion ratio of 225 U epoetin to 1 mg darbepoetin per the manufacturer's suggestion (23, 24) . Patient characteristics, the cumulative dosage of darbepoetin or epoetin, and clinical outcomes were obtained through review of the medical record. All data were collected and managed using REDCap, an electronic data capture tool hosted by our institution (25) . The study was approved by our Institutional Review Board.
These potential benefits of ESAs in LVAD-
PROCEDURAL TECHNIQUE. The HeartMate II left ventricular assist system has been described previously (26, 27) . All patients in this cohort were implanted through a median sternotomy using cardiopulmonary bypass. Following implant, patients were monitored in the cardiothoracic intensive care unit for complications and received transfusion of blood products at the discretion of the care team.
Anticoagulation and antiplatelet protocols changed over time and are shown in the Online Table 1 . 
Nassif et al. A 2-sided p value <0.05 was considered significant.
The p values presented do not adjust for multiple comparisons. All statistical analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, North Carolina).
RESULTS
PATIENT CHARACTERISTICS. Most patients were male (81%), classified as INTERMACS profile 2, and bridge-to-transplant approach was used for 68% of the 221 patients ( Table 1 ). The ESA cohort was more likely to have had bacteremia during index hospitalization than the control cohort (13% vs. 4%; p ¼ 0.02).
There were no significant between-cohort differences in rates of intracardiac thrombus, creatinine clear- A significant association between cumulative ESA dosage and the primary endpoint was observed (Online Table 3 ). For every 100-unit increase in equivalent ESA dosage, the hazard of suspected pump 
DISCUSSION
The results of our study suggest that use of ESAs in patients receiving LVAD support is associated with a significant increase in rates of suspected pump thrombosis and all-cause mortality.
It is unclear whether anemia independently contributes to increased mortality in advanced heart failure or simply acts as a marker of disease severity. Contrary to other studies, ESA use in our study was not associated with higher rates of stroke (20) . It is possible that subjects in the ESA cohort were more likely to manifest thrombotic events as pump thrombosis and were thus censored before any strokes occurred. Additionally, it is likely that the use of ESAs as a time-dependent variable leads to an underestimation of overall stroke in the ESA group.
No event could be attributed to the ESA group until they had received a dose of ESA. Since the first dose of ESA was given an average of 14 days after implant, any perioperative neurologic event in this group would not be included. However, the control group would include any perioperative events, likely increasing the prevalence of stroke. Finally, it is likely that any patient who had a stroke would not have received ESAs given that they are known to increase rates of stroke (20) .
Our data support recent analyses performed by
INTERMACs and others, which reveal a small but statistically significant increase in rates of pump thrombosis in the past few years (Online Table 5 ) (28, 38) . Our analysis demonstrated a nearly 16 ESAs had greater degrees of multiorgan dysfunction and shock than the control cohort. The Heartmate II risk score is better at predicting mortality than INTERMACS profile, however, the data available to us did not allow this calculation for all patients (39).
Additionally, our secondary endpoints should be interpreted with caution as no adjustments were made for multiple comparisons, thereby increasing the chances of a type I error. Finally, length of stay (LOS) was not included in our propensity score model as our institutional data has shown LOS has
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